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Multislice computer tomography (MSCT) 
for the optimisation of transcatheter 
aortic valve implantation (TAVI)
and 3-D TEE can evaluate all anatomical aspects of the aortic 
root.(6-8) MSCT is particularly attractive for the evaluation of 
anatomy because it provides the user with a 3-D virtual repre-
sentation that can be viewed from any angle or cut-plane after 
acquisition. What follows is a review of the role of MSCT pre-and 
post-TAVI.  
DIAGNOSIS OF SEVERE AORTIC STENOSIS
The diagnosis of severe aortic stenosis is typically based on 
measurements obtained from transthoracic echocardiography 
(TTE). The most frequently used measurement is a peak trans-
valvular flow velocity >4m/s or alternatively an aortic valve area 
(AVA) <1.0cm2, as calculated from the continuity equation, or an 
indexed aortic valve area <0.6cm2/m2. In cases where alternative or 
ancillary measurements are needed AVA is measured by either 
planimetry on MSCT or CMRI.(910) Many studies have reported a 
reasonably good correlation between the AVAs from MSCT 
planimetry and the continuity equation (TTE).(11) Yet, a limitation 
of the continuity equation is the requirement of a left ventricular 
outflow tract (LVOT) diameter measurement and the assumption 
of a circular LVOT for the calculation of LVOT area. This is because 
studies using 3-D imaging modalities including MSCT have 
demonstrated that the LVOT is oval shaped, a fact which cannot 
be appreciated on 2-D echocardiography.(10,12,13,) In 3 separate 
studies the assumption of circularity of the LVOT was abandoned 
when using the continuity equation and instead the LVOT area 
measured on MSCT was used to replace the LVOT diameter from 
TTE for the calculation of AVA.(14,15,16) These studies reported that 
the correlation between MSCT planimetered AVA and TTE 
calculated AVA improved substantially. 
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INTRODUCTION
Severe symptomatic aortic stenosis is found in 1% of patients aged 
65 to 75 and 5% of patients aged over 75 years.(1) Surgical aortic 
valve replacement (SAVR) is a life saving treatment, but for the 
approximately one third of patients who are ineligible for SAVR 
the prognosis is poor with <50% survival within 1 year.(2,3) Trans-
catheter aortic valve implantation (TAVI) is a new treatment option 
for patients who are not eligible for surgery due to high levels of 
co-morbidity. In this patient group the multicentre randomised 
PARTNER trial demonstrated that TAVI improved prognosis and 
quality of life when compared to medical therapy.(3)  
In contrast to open surgery, which proceeds under direct vision, 
TAVI relies on imaging.  Pre-procedural imaging is used to: Select 
patients who are anatomically suitable for TAVI; determine the 
vascular access route;  size (sizing helps match prosthesis size to 
patient anatomy); guide the implantation procedure; and to evaluate 
the result. In the majority of procedures where patients received a 
TAVI prosthesis thus far contrast angiography (CA) and 2-D 
echocardiography - either transthoracic (TTE) or transoesophageal 
(TEE) - were used to execute all these steps.(4,5) However, the 
aortic root has a complex 3-D anatomy, including crown-shaped 
leaflet attachments and a non-circular basal plane or annulus, which 
imposes limitations on 2-D imaging modalities such as CA or TTE/
TEE. In contrast 3-D imaging modalities such as multislice computer 
tomography (MSCT), cardiac magnetic resonance imaging (CMRI) 
Transcatheter aortic valve replacement (TAVI) is a novel 
therapy that is increasingly used to treat patients with 
severe aortic stenosis at high risk for surgical valve 
replacement. Patient selection, procedural planning and 
evaluation all require a detailed analysis of patient anatomy. 
The role and added value of multislice computer tomo-
graphy (MSCT) is described as a 3-D imaging modality that 
enables a comprehensive evaluation of the complex 3-D 
anatomy of the aortic root, planning of all potential trans-
catheter access routes and evaluation of prosthesis anatomy 
interactions post-implantation. SAHeart 2012; 9:14-25 
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Interestingly the majority of studies that examined the diagnostic 
accuracy of MSCT planimetry for the diagnosis of severe aortic 
stenosis used as comparator TTE AVA based on the continuity 
equation.(11) This can be viewed as a limitation given that the gold 
standard for the diagnosis of aortic stenosis in patients with 
preserved left ventricular function is peak transvalvular flow 
velocity from TTE. There are also technical limitations with 
measuring AVA by planimetry including obtaining a true short axis 
viewing plane when using TEE and signal loss caused by calcium. 
Ultimately it is the physiological limitation in flow that causes 
symptoms and reduces prognosis in aortic stenosis so that 
diagnostic parameters incorporating flow have a fundamental 
advantage over AVA planimetry, which is purely anatomical.  
A proof of concept study recently described a technique for 
measuring transaortic peak flow velocity on MSCT.(17) The diag-
nostic accuracy of AVA and indexed AVA from MSCT planimetry 
was found to be moderate when compared to a gold standard of 
transvalvular peak flow obtained with TTE. MSCT derived peak 
flow velocity and showed a better sensitivity and specificity 
(respectively 100% and 76%) for the diagnosis of severe aortic 
stenosis than did aortic valve area (respectively 74% and 76%) or 
indexed aortic valve area (respectively 74% and 65%). Whether 
this technique may be useful in patients with low flow and a 
preserved ejection fraction has not yet been studied. 
The diagnosis of severe aortic stenosis is often more complex in 
patients with poor ventricular function. This is because patients 
with a low ejection volume may not generate a high transvalvular 
gradient even in the presence of severe aortic stenosis, so called 
low flow, low gradient aortic stenosis. Alternatively, in patients with 
non-stenosed aortic leaflets the ejection fraction may be insufficient 
to fully open the aortic valve, so called pseudostenosis.(18) Dobuta-
mine stress echocardiography is generally used to differentiate 
true aortic stenosis from pseudostenosis by increasing the trans-
valvular flow. A recent study reported an association between the 
degree of aortic root calcification (AVC) and aortic stenosis severity 
in a validation cohort of 179 patients with preserved left ventricular 
function (LVF), which was then tested as a diagnostic marker in a 
testing cohort of 49 patients with impaired LVF.(19) In the testing 
cohort an AVC threshold of >1651 Agatston units, when com-
pared to a gold standard of dobutamine stress echocardiography, 
had a sensitivity of 95% and a specificity of 89% for the detection 
of severe aortic stenosis. The authors concluded that AVC 
measured on MSCT may help to identify patients with a low 
ejection fraction who may benefit from TAVI or SAVR.   
ELIGIBILITY
Pre-procedural imaging is used to evaluate the suitability of the 
aortic root for the deployment and secure lodgement of one of 
the TAVI prosthesis types and sizes as well as the feasibility of 
transcatheter delivery of the prosthesis (Figure 1).  There are 2 
commercially available prostheses namely the Edwards SAPIEN 
balloon expandable device (ESD) and the Medtronic Corevalve 
self-expanding device (MCS) (Figure 2, 3). The design and deploy-
ment features have been extensively described.(4,5,20) Potential 
candidates for TAVI are screened based on anatomical eligibility 
guidelines, which are device-specific due to the differences in 
the design and geometry between the MCS and ESD (Figure 1). 
The eligibility guidelines provided by industry have recently been 
summarised.(21)
Aortic root dimensions
The features of the aortic root that are evaluated during screening 
are shown in Figure 1. An integrated interpretation is helpful, for 
example: The combination of a low origin of the ostium of the left 
main stem in combination with a relatively small sinus of Valsalva 
dimension may risk occlusion of the left main stem, because the 
deployment of the TAVI prosthesis displaces the calcified native 
leaflets, in contrast to SAVR where decalcification precedes implan-
tation. On the other hand, provided that the sinus of Valsalva is 
wide enough to accommodate the displaced calcium, a low origin 
of the left main stem is unlikely to cause a problem. Due to the 
hour glass shape of the MCS the narrowest section of the frame 
will be positioned at the level of the coronary ostia, provided that 
a satisfactory depth of implantation is obtained following device 
deployment, a design feature that probably reduces the risk of 
coronary obstruction. The dimensions of the aortic annulus or basal 
plane are used to determine whether the aortic root can accom-
modate one of the TAVI prosthesis sizes. 
Sizing
The aortic annulus or basal plane is defined anatomically as the 
virtual ring with 3 anchor points at the nadirs of the 3 leaflets of the 
crown shaped aortic valve(22,23) (Figure 2). The dimensions of the 
aortic annulus are used to select the prosthesis size for which the 
patient may be eligible. The MCS comes in three sizes based on the 
nominal inflow diameter. The 26mm inflow diameter is meant 
for an annulus of 20-23mm and the 29mm for an annulus of 
23-27mm and the recently introduced 31mm inflow for an annulus 
of 27-29mm. The Edwards prosthesis comes in sizes 23 and 26mm 
respectively meant for annuli of 18-21mm and 22-24mm and a 
29mm device, which can be delivered only via the transapical 
route, designed for annuli of 25-29mm. The differences in size 
between the ESD and the MCS means that the majority of patients 
will be eligible for one of the two prostheses types.(24)
Although the sizing guidelines are straightforward the measure-
ment of the aortic annulus diameter by non-invasive imaging is not 
as simple as might be implied. Studies using 3-D imaging modalities 
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including MSCT, CMRI and 3-D TTE/TEE have shown that the 
aortic annulus is not round but oval in shape(10,12,13,25) (Figure 3).  In 
one study using MSCT to evaluate the aortic root in 75 patients 
who were candidates for TAVI an oval annulus was seen in approxi-
mately 78% of patients.(26) By implication a minimum and maximum 
diameter could be measured and the difference between the 2 was 
on average 6.5mm (95% confidence interval 5.7-7.2). The TTE 
parasternal long axis view and TEE 3-chamber, both of which are 
routinely used for sizing, allow only measurement of an oblique 
sagittal diameter, which approximates the minimum diameter of 
the aortic annulus.(27) The coronal, which approximates the maxi-
mum diameter, cannot be measured on TTE/TEE(6,28) (Figure 3). 
The mean annulus diameters derived from any of the arithmetic 
mean, perimeter or area barely differ from each other and fall in 
between the minimum and maximum.(26) The annulus diameter 
measured a TTE PLAX view or TEE 3 chamber view falls in between 
the mean and the minimum diameter, and the coronal diameter 
from contrast aortography falls in between the mean and maximum 
diameters.(27,28) The differences between the imaging modalities 
represent anatomically different dimensions of a complex structure 
rather than discrepancies, (Figure 3), whereas a lesser contribution 
may be expected from measurement variability and -method. 
Figure 3 shows how these measurements relate to one another 
based on an axial image of the aortic annulus. The use of the 
different diameter measurements has substantial implications for 
the selection of prosthesis size. One study examined sizing for 
the ESD by either MSCT or TTE and TEE in 45 patients.(27) If 
sizing were based on MSCT mean diameter 38% of patients would 
not have been eligible for an ESD (due to the annulus being too 
large) whereas respectively 24% and 33% were ineligible based 
on TTE and TEE. The authors concluded, based on the results of 
their current practice, that sizing should be based on TTE/TEE. 
MSCT FOR THE OPTIMISATION OF TAVI
FIGURE 1:  Anatomical eligibility criteria for TAVI are all evaluable on MSCT
Panel A: A MSCT oblique coronal view shows diameter measurements indicated in blue and height measurements in green. Panel B shows a corresponding 
view on contrast aortography. Panel C shows the oblique sagittal view. The insets are short-axis images at the levels indicated allowing planimetry of the 
aortic valve area (level 2) and detailed evaluation of the aortic annulus or basal plane (level 1).  
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Another study examining the hypothetical effects of sizing for the 
MCS by different MSCT diameter measurements in 75 patients 
reported that 26% to 39% of patients would not be eligible for a 
MCS if sizing were based on the minimum and maximum 
diameters(26) respectively. Sizing based on any of the mean annulus 
diameter measurements resulted in 90% of patients being eligible 
for the MCS. The lower rate of eligibility due to an overly large 
annulus based on MSCT mean annulus diameter in the study of 
the ESD when compared to the study with the MCS is explained 
by the fact that at the time of the study, only the 2 smaller sizes 
of ESD were available. Another study compared different dia-
meter measurements of the aortic annulus on pre-TAVI MSCT 
(minimum, maximum, coronal, sagittal, mean from cross-sectional 
area [CSA]) with the inflow diameter achieved post-implantation 
with the ESD in 24 patients.(29) The post-implantation ESD diameter 
correlated strongly with mean diameter from native annulus CSA 
(r=0.84, p<0.01) whereas the correlation with all the other dia-
meter measurements were moderate to poor (all r<0.65). Another 
study that obtained MSCT pre- and post-TAVI with the MCS in 30 
patients also reported that the post-implantation cross-sectional 
area achieved at the inflow of the MCS frame was most similar to 
the mean diameter and the CSA of the native annulus pre-
implantation.(30) Despite these interesting observations there are 
no randomised data on which approach to sizing gives the best 
outcome. An important point is that the recent availability of more 
prosthesis sizes increases the proportion of eligible patients but 
also the potential adverse effects of a sizing error. Data that suggest 
an effect of sizing on outcome, but not which sizing strategy to use, 
is discussed in a later section.  
FIGURE 2:  Sizing for TAVI is based on the dimensions of the aortic annulus
Sizing for both Edwards SAPIEN (A) and Medtronic CoreValve (D) devices is based on the “diameter” of the aortic annulus. Anatomically the aortic 
valve is crown-shaped (B) and the aortic annulus is not an anatomical entity but rather a virtual ring with 3 anchor points at the nadirs of the 3 aortic 
leafl ets (green line, C). On angiography the level of the aortic annulus can be localised before (E) and after (F) TAVI. The inset (G) shows on a short-axis 
view from MSCT that the aortic annulus is usually oval-shaped so that more than one diameter measurement is required to describe its dimensions.  
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Vascular access
All 3 available prosthesis sizes of the MCS 3rd generation and the 
23mm ESD are deliverable through an 18F transvascular sheath, 
whereas the 26mm ESD requires a 19F sheath. Transapical delivery 
is possible for all the ESD-XT prosthesis sizes and is the only route 
of access possible with the 29mm ESD. The gold standard for 
the assessment of vascular access route is invasive angiography, 
which may require multiple-contrast injections to obtain a vascular 
overview of the aortic root, arch abdominal aorta and iliac-femoral 
arteries.(31) 
Multiple studies have shown that MSCT is an excellent diagnostic 
tool for the detection of significant stenosis in the peripheral 
vasculature.(32) MSCT is increasingly being used for the more 
demanding role of screening vascular access routes for TAVI.(33,34) 
The advantage is that an overview of all potential vascular access 
routes, including transfemoral, -subclavian or -apical may be 
obtained,(35) (Figure 4). In a combined scanning protocol the vas-
cular overview can be obtained immediately following a scan of 
the heart without requiring additional contrast. 
With modern scanning techniques, such as prospective ECG 
synchronised high pitch (flash), only an incremental increase in 
radiation dose is required above that of the heart scan.(35) In addi-
tion to information on vascular luminal diameter MSCT provides a 
detailed overview of the 3 dimensional tortuosity and calcification 
of the vascular tree. All 3 these factors have to be considered when 
choosing the access route in order to deduce permissibility for the 
FIGURE 3: MSCT facilitates understanding of which dimensions of the aortic annulus may be measured with different imaging modalities
The left column shows an oblique sagittal view on MSCT (top) corresponding to the parasternal long axis view on transthoracic- and the 3 chamber 
view on transoesophageal echocardiography (bottom). The right column shows an oblique coronal view on MSCT (top) corresponding to an antero-
posterior type view on contrast angiography (bottom). On a short-axis view of the aortic annulus (inset, middle column) the diameter measurements 
obtained from echocardiography (green) and angiography (yellow) are indicated as well as the true minimum and maximum dimensions (blue), which 
are not readily appreciable on echocardiography or angiography in approximately one third of patients. 
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relatively rigid undeployed TAVI prostheses,(34,31) (Figure 4, 5). In 
addition to planning access via the transfemoral and subclavian 
arteries MSCT allows evaluation of transapical and direct access 
routes, including the optimal ribspace and direction of puncture for 
true percutaneous procedures, (Figure 6). TTE is at present much 
more widely used for  determining the point of entry for transapical 
access. On the other hand, TTE may not be useful for direct aortic 
access due to the interposition of lung tissue although experience 
with this approach is limited. 
An important point is that MSCT tends to exaggerate the thick-
ness of calcification. This means that in the presence of dense 
calcification, in particular if it is semi-circumferential or worse, the 
lumen diameter may be either over- or underestimated depending 
on the measurement technique. Caution is warranted with near 
circumferential calcium even with a clearly permissible lumen 
diameter due to the increased rigidity of the vessel and the con-
sequent resistance to passage of a relatively large device. A study of 
129 patients who received either an ESD (102 patients) or a MCS 
(27 patients) investigated the determinants of major vascular 
complications as defined by Vascular Academic Research Con-
sortium (VARC) criteria.(34) Major determinants in multivariate 
analysis were the ratio of sheath outer diameter to femoral artery 
minimum lumen diameter (SFAR) and femoro-iliac artery calci-
fication. A SFAR of >1.05 was also associated with increased 
mortality.
FIGURE 4: A vascular overview obtained from MSCT
A 3-dimensional reconstruction shows an overview of tortuosity and calcifi cation (middle). A detailed interrogation of lumen diameter and the amount 
and degree of circumferentiality of calcifi cation is performed on multiplanar reformatted images (left, right and inset showing a short-axis view). 
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PROCEDURAL GUIDANCE
Contrast angiography (CA) is likely to remain the standard imaging 
technique for guidance for the foreseeable future. Two aspects that 
may improve procedural guidance include the use of the optimal 
projection (OP) and new developments in software aimed at 
facilitating positioning during device deployment. 
Optimal projection
The OP is defined as the C-arm angulation that will show the 3 
aortic sinuses aligned on one plane and separated so that all 3 
sinuses are clearly distinguishable. The optimal projection can be 
obtained from pre-procedural MSCT.(36,37,38) In brief this is done by 
first setting up a short-axis plane of the aortic annulus, then parallel 
shifting it to the level of the coaptation of the aortic leaflets. 
Following this, the cross-hairs are rotated so that one plane runs 
along the coaptation line of the non- and left-coronary and through 
the middle of the right coronary sinus and finally by reading off 
the viewing angle of the orthogonal (oblique coronal) plane. If 
pre-procedural MSCT is not available multiple contrast injections 
may be needed with adjustment of the C-arm angulation to obtain 
the correct view. The use of the OP during TAVI avoids overlap 
and consequent confusion of the sinuses. In one small study the 
use of the OP obtained from pre-procedure MSCT resulted in a 
better final implantation depth of the ESD when compared to 20 
subsequent patients who did not have pre-procedure MSCT.(36) 
The optimal projection also makes possible accurate evaluation of 
depth of implantation, which is important in evaluating the potential 
causes and subsequent corrective steps required (balloon dilata-
tion if the depth is optimal, a valve-in-valve procedure if it is 
positioned too deep) in the event that significant paravalvular 
aortic regurgitation (PAR) is seen post-deployment.(39) 
HOW TO INTERROGATE AN MSCT PRE-TAVI
A step-by-step method for defining the aortic annulus on MSCT 
and the different measurements has been described using a 
FIGURE 5: Evaluation of tortuosity
A 3-D vascular overview showing signifi cant tortuosity of the femora-iliac vessels and the thoraco-abdominal aorta (left). The multiplanar reformatted 
images allow measurement of lumen diameter of the subclavian artery (top, middle). As the artery crosses the fi rst rib there is a severe angulation that 
can be appreciated in the poster-superior view (green), but not in the antero-posterior view (red).
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conventional MSCT workstation as well as dedicated TAVI-planning 
software that reduces the amount of user input required and 
speeds up the analysis process.(6)  
EVALUATION
After device release the depth of implantation, frame expansion 
and degree of aortic regurgitation are of interest. MSCT allows a 
detailed evaluation of frame expansion, asymmetry and apposition 
to surrounding tissue on short axis images (Figure 7). This applies 
to both the ESD and the MCS.(30,40)  Although MSCT of the frame 
is not routinely required for clinical management it may be valuable 
in understanding the cause of complications in selected cases for 
example where there is a high residual gradient, unexplained aortic 
regurgitation or a question about coronary impingement.(41,42,43)
THE EVOLVING ROLE OF DIFFERENT IMAGING 
MODALITIES
A more detailed understanding is emerging of anatomical features, 
in addition to those described in the industry defined eligibility 
guidelines, which may affect the outcome of TAVI. These data are 
from case series and have focused on predictors of intermediate 
outcomes including paravalvular aortic regurgitation, the need for 
balloon post-dilatation, device dislodgement and new conduction 
abnormalities or pacing requirement.  
Paravalvular aortic regurgitation and the need for balloon 
post-dilatation
Haemodynamically significant aortic regurgitation after TAVI is 
poorly tolerated and is immediately corrected during the 
implantation procedure by either post-dilatation or, if the cause is a 
FIGURE 6: Planning of transapical and other unusual approaches on MSCT
Planning for a transapical approach shows the optimal rib space and direction of puncture (top row). In patients with no other options direct aortic 
access via a mini-thoracotomy has been described and the potential catheter path can be planned with MSCT (bottom row).   
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too deep position of the implanted prosthesis, implantation of a 
second prosthesis (valve-in-valve). Residual paravalvular aortic 
regurgitation of a mild or more severe degree is common after 
TAVI occurring in between 15 and 50% of cases.(44,45,46,47.48) Although 
mild to moderate PAR after SAVR is not thought to adversely affect 
haemodynamics a recent retrospective multicentre registry found 
an association of mild to moderate PAR (defined as ≥2/4) with 
increased mortality in TAVI patients.(46) The data suggested that 
residual PAR is a marker of an adverse risk profile and it is not clear 
whether reducing the degree of PAR may also reduce risk of 
adverse events in the present TAVI population. 
The intention of industry guidelines for prosthesis size selection is 
for some degree of over-sizing to ensure a reasonable force of 
apposition of the sealing skirt to the surrounding tissue in order to 
ameliorate PAR and ensure positional stability. Imaging studies of 
the aortic root using either TTE or MSCT have found that resi-
dual PAR was associated with larger aortic annulus dimensions 
and a lower ratio of nominal prosthesis to annulus diameter, 
indicating that a lesser degree of over-sizing may be associated with 
PAR.(44,45,49,50) In these studies there was substantial overlap in the 
prosthesis to annulus ratio between patients with and without 
mild to moderate PAR, indicating that other factors also play a role. 
FIGURE 7: MSCT after TAVI
The top row shows a Medtronic CoreValve device implanted in a patient with very severe calcifi cation of the aorta-mitral fi brous continuity. The coronal 
view (left) shows a relatively high implant. Short-axis views at different levels as indicated show calcifi cation causing frame asymmetry and malapposition 
at the infl ow (1), a chunk of calcium coming close to, but not obstructing the left main stem (2), and a near normal circularity of the frame and expansion 
at the functionally important level of coaptation of the leafl ets (3). The interaction between the frame and calcifi cation of the aortic valve and mitral 
annulus are shown in a maximum intensity projection (right). 
The bottom row shows an early implant of a Medtronic CoreValve device that was relatively deep as seen in the coronal view (left) and restricts mitral 
valve opening as seen in the sagittal view (middle). A 3-D reconstruction of the frame from MSCT is shown on the right. 
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A small study of 54 patients localised the jets of PAR around the 
MCS prosthesis inflow in relation to the native anatomy and found 
that PAR was most common on the inside curve of the aortic arch, 
which is also the left side of the largest diameter of the aortic 
annulus, and at the aorta-mitral fibrous continuity.(45) In the same 
study MSCT post-TAVI demonstrated that mal-apposition of the 
device frame to the surrounding tissue was also more frequent at 
these two anatomical locations. The authors concluded that the 
angulation of the aorta in addition to sizing and calcification may 
contribute to the etiology of PAR after TAVI with an MCS.(45) In 
other studies mild to moderate PAR was also associated with a 
higher degree of calcification of the aortic root.(39,50) In patients with 
a more than moderate degree of PAR immediately after TAVI, 
balloon post-dilatation is usually the first step to reduce it. 
A case series of 100 patients who received a MCS and where post-
dilatation was performed in 30% quantified the degree of aortic 
root calcification on pre-procedural MSCT. In that study an aortic 
root Agatston score >3 000 associated with post-dilatation and 
was positively correlated with the final degree of regurgitation.(39) 
Another study of 110 patients who received the MCS and where 
post-dilatation was performed in 11 cases found that the need for 
balloon post-dilatation was associated with larger annulus diameter, 
a lower ratio of prosthesis to annulus size and the degree of 
calcification of the aortic root or leaflets.(51) In that study the ability 
to discriminate the need for balloon post-dilatation was poor for 
the prosthesis to annulus ratio (area under a ROC curve 0.3), 
moderate for annulus dimensions (area under ROC curve 0.67) 
and excellent for calcification (area under ROC curve >0.8).(51) 
These data indicate that calcification is the most-important deter-
minant of significant PAR and the need for post-dilatation and 
may, in future, lead to the testing of new procedural strategies 
intended to reduce PAR in patients known to have very dense 
aortic root calcification.  
Device dislodgement
Late (post-implantation procedure) dislodgement of the TAVI 
prosthesis is rare. In one case report it was thought to be related 
to low levels of calcification of the aortic leaflets, poor left ventri-
cular function and possibly to undersizing.(52) Predictors of intra-
procedural device dislodgement, which required device retrieval 
and repeated implantation in the correct position, were investi-
gated in one study of 98 patients.(53) Device dislodgement occur-
red in 18 of the patients and was associated with larger aortic valve 
area and a lower degree of aortic root calcification. In multivariate 
analysis an aortic root calcium threshold of <2 359 (Agatston 
score) was the only independent predictor for valve dislodgement 
(OR 3.1, 95% confidence interval 1.1 - 8.8). The authors proposed 
that, in patients with low levels of aortic root calcification device 
deployment during rapid pacing may be considered to avoid 
dislodgement during the deployment stage.(53)   
New conduction abnormalities or pacing requirement 
New conduction abnormalities requiring implantation of a per-
manent pacemaker are higher after TAVI than after SAVR. The rate 
of implantation of permanent pacemakers in patients with a MCS 
ranges from 9 to 39%.(54-56) Anatomical factors identified on MSCT 
that were associated with pacemaker requirement include a higher 
prosthesis to annulus ratio and a higher pre-dilatation balloon to 
annulus ratio.(55,57) Whether aortic root calcification is associated 
with pacemaker requirement is controversial.(58,59)
Iatrogenic membranous VSD 
Iatrogenic membranous VSD is uncommon after TAVI but may 
have adverse consequences.(41,60) A case report described the 
occurrence of iatrogenic VSD following post-dilatation of the TAVI 
prosthesis with a relatively oversized balloon in a patient with an 
unusually long ventricular membranous septum. The unusual ana-
tomic finding of a long ventricular extent of the membranous 
septum was readily discernable on pre-implantation MSCT in a 
small series of patients.(41)
CONCLUSIONS: 
THE EVOLVING ROLE OF IMAGING
The use of MSCT for planning TAVI has improved our under-
standing of the role and limitations of commonly used 2-D imaging 
modalities including CA and TTE/TEE and is contributing to a more 
detailed understanding of anatomical factors, identifiable on pre-
procedural imaging that may impact on procedural outcome. 
Most of these observations come from case series and as such 
the data need to be confirmed. However, a detailed under-
standing of patient anatomy obtained from MSCT will increasingly 
lead to a tailored patient-specific approach to optimise the out-
come of TAVI.
Conflict of interest: none declared.
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